Army taps Vermillion for ovarian cancer Dx study

04/18/2013 | GenomeWeb Daily News (free registration)

The U.S. Army Medical Research and Materiel Command awarded Vermillion a contract to investigate the cost-benefits profile of the company's OVA1 test for ovarian cancer. The company will examine the assay's clinical use in managed care environments, and a multicenter clinical trial will evaluate the test as a presurgical standard of care in women who have pelvic masses.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC